Literature DB >> 26840144

Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.

Hossein Borghaei, Julie Brahmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26840144     DOI： 10.1056/NEJMc1514790

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

Review 1.  Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.

Authors:  Grainne M O'Kane; Natasha B Leighl
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.

Authors:  Tao Fan; Yu Liu; Hengchang Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shungeng Gao; Chunxiang Li; Jie He
Journal:  Cancer Immunol Immunother       Date:  2021-05-11       Impact factor: 6.968

3.  PD-L1 Expression in Pancreatic Cancer.

Authors:  Lei Zheng
Journal:  J Natl Cancer Inst       Date:  2017-01-28       Impact factor: 13.506

4.  Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

Authors:  Xiuning Le; Deepa Rangachari; Daniel B Costa
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

5.  Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2019-10-24       Impact factor: 44.544

6.  Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.

Authors:  Deepa Rangachari; Paul A VanderLaan; Meghan Shea; Xiuning Le; Mark S Huberman; Susumu S Kobayashi; Daniel B Costa
Journal:  J Thorac Oncol       Date:  2017-01-16       Impact factor: 15.609

7.  Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.

Authors:  Andrew C Tiu; Rashmika Potdar; Djeneba Audrey Djibo; Muhammad Masab; Claudia Dourado
Journal:  Med Oncol       Date:  2018-06-18       Impact factor: 3.064

8.  Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.

Authors:  Osama Mohamad; Alberto Diaz de Leon; Samuel Schroeder; Andrew Leiker; Alana Christie; Elizabeth Zhang-Velten; Lakshya Trivedi; Saad Khan; Neil B Desai; Aaron Laine; Kevin Albuquerque; Puneeth Iyengar; Yull Arriaga; Kevin Courtney; David E Gerber; Hans Hammers; Hak Choy; Robert Timmerman; James Brugarolas; Raquibul Hannan
Journal:  Oncoimmunology       Date:  2018-03-15       Impact factor: 8.110

Review 9.  Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.

Authors:  Lars M Wagner; Val R Adams
Journal:  Onco Targets Ther       Date:  2017-04-12       Impact factor: 4.147

10.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Authors:  J Mazieres; A Drilon; A Lusque; L Mhanna; A B Cortot; L Mezquita; A A Thai; C Mascaux; S Couraud; R Veillon; M Van den Heuvel; J Neal; N Peled; M Früh; T L Ng; V Gounant; S Popat; J Diebold; J Sabari; V W Zhu; S I Rothschild; P Bironzo; A Martinez-Marti; A Curioni-Fontecedro; R Rosell; M Lattuca-Truc; M Wiesweg; B Besse; B Solomon; F Barlesi; R D Schouten; H Wakelee; D R Camidge; G Zalcman; S Novello; S I Ou; J Milia; O Gautschi
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.